BioMarin to Acquire Amicus for $4.8B, Boosting Rare Disease Leadership and Growth
BioMarin is acquiring Amicus Therapeutics for $4.8 billion to expand its portfolio in rare disease treatments, including marketed products Galafold and Pombiliti + Opfolda, which generated $599 million in revenue over the past four quarters. The deal aims to accelerate revenue growth, diversify BioMarin's product offerings, and create shareholder value, with the transaction expected to close in Q2 2026 and be immediately accretive to earnings.